Ernexa Therapeutics annual debt-to-ebitda ratio
2010
2012
2013
2016
2017
2018
2019
Ernexa Therapeutics Debt-to-EBITDA Ratio Growth & History (ERNA)
Ernexa Therapeutics's debt-to-ebitda ratio was 5.45 for fiscal 2019.
View full Ernexa Therapeutics company overviewErnexa Therapeutics annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2019 | 2019-12-31 | 5.45 | 2.99 | +121.81% |
| 2018 | 2018-12-31 | 2.46 | −3.51 | −58.82% |
| 2017 | 2017-12-31 | 5.97 | −8.03 | −57.35% |
| 2016 | 2016-12-31 | 14.00 | — | — |
| 2013 | 2013-12-31 | 0.97 | 0.91 | +1529.89% |
| 2012 | 2012-12-31 | 0.06 | — | — |
| 2010 | 2010-12-31 | 0.17 | — | — |
Ernexa Therapeutics quarterly debt-to-ebitda ratio
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2019 | 2019-12-31 | 5.45 | 2.99 | +121.81% |
| Q3 2019 | 2019-09-30 | 1.76 | 1.08 | +157.54% |
| Q2 2019 | 2019-06-30 | 1.43 | −0.21 | −12.95% |
| Q1 2019 | 2019-03-31 | 1.42 | −0.07 | −4.97% |
| Q4 2018 | 2018-12-31 | 2.46 | −3.51 | −58.82% |
| Q3 2018 | 2018-09-30 | 0.68 | −3.10 | −81.91% |
| Q2 2018 | 2018-06-30 | 1.65 | −3.33 | −66.92% |
| Q1 2018 | 2018-03-31 | 1.49 | −15.03 | −90.96% |
| Q4 2017 | 2017-12-31 | 5.97 | −8.03 | −57.35% |
| Q3 2017 | 2017-09-30 | 3.78 | −9.72 | −72.01% |
| Q2 2017 | 2017-06-30 | 4.98 | — | — |
| Q1 2017 | 2017-03-31 | 16.52 | — | — |
| Q4 2016 | 2016-12-31 | 14.00 | — | — |
| Q3 2016 | 2016-09-30 | 13.50 | — | — |
| Q2 2014 | 2014-06-30 | 0.57 | 0.54 | +1872.15% |
| Q1 2014 | 2014-03-31 | 0.06 | 0.01 | +21.58% |
| Q4 2013 | 2013-12-31 | 0.97 | 0.91 | +1529.89% |
| Q3 2013 | 2013-09-30 | 0.03 | −0.24 | −87.78% |
| Q2 2013 | 2013-06-30 | 0.03 | — | — |
| Q1 2013 | 2013-03-31 | 0.05 | — | — |
| Q4 2012 | 2012-12-31 | 0.06 | — | — |
| Q3 2012 | 2012-09-30 | 0.27 | — | — |
Ernexa Therapeutics debt-to-ebitda ratio trends
Between the periods ended 2010-12-31 and 2019-12-31, Ernexa Therapeutics's debt-to-ebitda ratio increased from 0.17 to 5.45, a change of 5.29. The latest reported quarter, Q4 2019, shows 5.45.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics source filings ↗